Detalles de la búsqueda
1.
Grade 3/4 Adverse Event Costs of Immuno-oncology Combination Therapies for Previously Untreated Advanced Renal Cell Carcinoma.
Oncologist;
28(1): 72-79, 2023 01 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-36124890
2.
Nivolumab versus placebo as adjuvant therapy for resected stage III melanoma: a propensity weighted indirect treatment comparison and number needed to treat analysis for recurrence-free survival and overall survival.
Cancer Immunol Immunother;
72(4): 945-954, 2023 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-36197494
3.
Temporal trends of adverse events and costs of nivolumab plus ipilimumab versus sunitinib in advanced renal cell carcinoma.
Future Oncol;
18(10): 1219-1234, 2022 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-34939424
4.
Correction to: Nivolumab versus placebo as adjuvant therapy for resected stage III melanoma: a propensity weighted indirect treatment comparison and number needed to treat analysis for recurrence-free survival and overall survival.
Cancer Immunol Immunother;
72(4): 955, 2023 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-36538061
5.
A Matching-adjusted Indirect Comparison of Nivolumab Plus Cabozantinib Versus Pembrolizumab Plus Axitinib in Patients with Advanced Renal Cell Carcinoma.
Eur Urol Oncol;
6(3): 339-348, 2023 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-36842942
6.
Temporal Trends in Grade 3/4 Adverse Events and Associated Costs of Nivolumab Plus Cabozantinib Versus Sunitinib for Previously Untreated Advanced Renal Cell Carcinoma.
Clin Drug Investig;
42(7): 611-622, 2022 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-35696045
7.
A Matching-Adjusted Indirect Comparison of Upadacitinib Versus Tofacitinib in Adults with Moderate-to-Severe Rheumatoid Arthritis.
Rheumatol Ther;
8(1): 167-181, 2021 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-33244703
8.
US cost-effectiveness of polatuzumab vedotin, bendamustine and rituximab in diffuse large B-cell lymphoma.
J Comp Eff Res;
9(14): 1003-1015, 2020 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-33028076
9.
Comparative Efficacy of JAK Inhibitors for Moderate-To-Severe Rheumatoid Arthritis: A Network Meta-Analysis.
Adv Ther;
37(5): 2356-2372, 2020 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-32297280
10.
Indirect Treatment Comparison of Nivolumab Versus Observation or Ipilimumab as Adjuvant Therapy in Resected Melanoma Using Pooled Clinical Trial Data.
Adv Ther;
36(10): 2783-2796, 2019 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-31440980
11.
First-line treatment disruption among post-menopausal women with HR+/HER2- metastatic breast cancer: a retrospective US claims study.
Curr Med Res Opin;
33(12): 2137-2143, 2017 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-28994315
12.
Real-world palbociclib dosing patterns and implications for drug costs in the treatment of HR+/HER2- metastatic breast cancer.
Expert Opin Pharmacother;
18(12): 1167-1178, 2017 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-28699804
13.
Matching-adjusted indirect comparisons of efficacy of BAY 81-8973 vs two recombinant factor VIII for the prophylactic treatment of severe hemophilia A.
J Blood Med;
7: 129-37, 2016.
Artículo
en Inglés
| MEDLINE | ID: mdl-27445511
14.
Authors' Response to Letter to the Editor Regarding Comparative Efficacy of JAK Inhibitors for Moderate-to-Severe Rheumatoid Arthritis: A Network Meta-Analysis.
Adv Ther;
38(5): 2750-2756, 2021 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-33742364
15.
Cost effectiveness of pharmacotherapies for attention-deficit hyperactivity disorder: a systematic literature review.
CNS Drugs;
26(7): 581-600, 2012 Jul 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-22712698
Resultados
1 -
15
de 15
1
Próxima >
>>